NIFTY 50

SP Tulsian continues to have a positive view on Aurobindo Pharma

Updated : September 06, 2018 15:41:19 IST

SP Tulsian discusses with Anuj Singhal and Surabhi Upadhyay his analysis on the fundamental side of the market as well as specific stocks and sectors.

On Aurobindo Pharma acquiring Sandoz’s dermatology and oral solid business, SP Tulsian said it looks to be quite positive and in fact, that has been the market response too.

"However, one thing which we wish to state for Aurobindo Pharma that this has been seen in an accumulation for the last couple of weeks and this breakout is seen to having given today about $900 million," Tulsian said.

Probably the upside is seen to be more, maybe of about 6-7 percent more where the renewed call has to be taken if you want to have the short term view of maybe about three months, he said.

"Otherwise we continue to have a positive view on Aurobindo Pharma,” Tulsian added.

Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you